Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $280.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by equities research analysts at Morgan Stanley from $245.00 to $280.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price target would indicate a potential upside of 11.30% from the stock’s current price.

A number of other research firms also recently commented on JAZZ. Leerink Partners lifted their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Royal Bank Of Canada upped their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. TD Cowen lifted their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Piper Sandler boosted their price target on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $264.17.

Jazz Pharmaceuticals Trading Down 0.5%

NASDAQ JAZZ opened at $251.58 on Tuesday. Jazz Pharmaceuticals has a 12 month low of $105.00 and a 12 month high of $261.30. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The company has a market capitalization of $15.80 billion, a price-to-earnings ratio of -12,572.71, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. The company’s fifty day moving average price is $239.50 and its two-hundred day moving average price is $207.30.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.Jazz Pharmaceuticals’s revenue was up 15.5% on a year-over-year basis. During the same period in the prior year, the business earned ($8.25) earnings per share. As a group, research analysts predict that Jazz Pharmaceuticals will post 21.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the transaction, the director directly owned 9,567 shares in the company, valued at $2,311,100.19. The trade was a 22.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark Douglas Smith sold 1,157 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $230.55, for a total value of $266,746.35. Following the completion of the transaction, the director owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. The trade was a 10.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently made changes to their positions in JAZZ. LRI Investments LLC bought a new position in Jazz Pharmaceuticals during the 4th quarter worth $38,000. Danske Bank A S bought a new stake in Jazz Pharmaceuticals in the third quarter valued at $40,000. Geneos Wealth Management Inc. lifted its stake in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Jazz Pharmaceuticals by 1,383.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares during the period. Finally, Leonteq Securities AG bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth about $50,000. Institutional investors own 89.14% of the company’s stock.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported second-quarter revenue of approximately $1.21 billion, up 15.5% year over year and above the $1.11 billion analyst estimate. Growth was supported by Xywav revenue increasing 13% and Epidiolex revenue rising 16%. Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its 2026 revenue outlook to $4.6 billion-$4.8 billion, above the roughly $4.5 billion consensus estimate. Jazz also said it is prepared to launch Ziihera in first-line HER2-positive gastric or gastroesophageal junction cancer immediately after potential FDA approval. Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Analysts became more bullish following the results. Needham raised its price target from $282 to $292 and maintained a “buy” rating, while Robert W. Baird increased its target from $252 to $280 and assigned an “outperform” rating. Benzinga analyst updates
• Negative Sentiment: Second-quarter adjusted earnings of $5.71 per share missed consensus estimates ranging from $6.04 to $6.18. Although results improved substantially from a loss of $8.25 per share a year earlier, the earnings shortfall may be weighing on the stock. Jazz Pharmaceuticals Q2 Earnings Lag Estimates

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.